According to J.P. Morgan, Johnson & Johnson JNJ is turning positive.
J.P. Morgan said that J&J has weathered a difficult couple of years, facing challenges on multiple fronts, including in 2008-09 generic competition for Risperdal and Topamax and the loss of significant DES share from increased competition. “In 2010, economic pressures weighed on both the Medical Device and Consumer segments, while Pharma dealt with Healthcare reform and newfound pricing pressures in Europe. Finally, McNeil has struggled through a series of highly public recalls, which led to the company signing a Consent Decree in March. These challenges have been reflected in the share performance, with the stock underperforming the S&P by 60% since the March 2009 market bottom.”
Johnson & Johnson closed yesterday at $62.69.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in